Editorial / About this project
About Rx KPV
A close reading of the KPV tripeptide record — what it establishes, what it does not, and where access stands.
What Rx KPV is
Rx KPV assembles the peer-reviewed record on the KPV peptide into a docket a careful reader can work through: cell studies, animal models, and reviews on one side, the FDA pages that govern compounded access on the other. It reads the literature; it does not offer a service. No clinic sits behind it, no clinician is on staff, and it dispenses no guidance about anyone's health. It makes nothing, stocks nothing, and sells nothing.
The method is deliberately conservative. Every quantitative claim — each concentration, percentage, duration, and outcome — is tied to a numbered citation, and the identifiers were checked against PubMed and Crossref rather than lifted from secondary write-ups, because PMID and DOI errors run rampant in web writing about KPV. Where the evidence is strong, the docket says so plainly. Where it is preclinical or simply absent, it says that too: KPV has no published human clinical trials, and marketing language is never allowed to stand in for data.
What the name means
The 'Rx' in Rx KPV is a reading posture, not a menu of services. It marks where this docket stands in relation to the literature — a regulatory-minded reading that takes the compounding-access and FDA 503A questions seriously — and it is not an offer of treatment, consultation, or a prescription. There is no pharmacy here, no line to a prescriber, and no path to obtaining anything. KPV is a research peptide with no FDA approval; the KPV legal status page reads that standing straight from FDA's own pages.
The distinction matters because anyone searching for a research peptide deserves a source that separates what the cited studies establish from what they do not, keeps promotional claims apart from data, and never dresses a scheduled regulatory discussion up as a settled decision. That is the bar this docket holds itself to.
How to use this digest
Start with the KPV colitis research page for mechanism and the strongest studies, then the PepT1-targeted delivery page for the delivery problem and gut uptake. The KPV dosage in research page describes research concentrations and routes, never a human regimen. The FDA 503A compounding access page covers the regulatory record. And the KPV frequently asked questions page answers the common questions directly. Everything here is information about the published science, not guidance for using any compound.